205 related articles for article (PubMed ID: 26104056)
1. Synthetic and Natural Monoamine Oxidase Inhibitors as Potential Lead Compounds for Effective Therapeutics.
Pathak A; Srivastava AK; Singour PK; Gouda P
Cent Nerv Syst Agents Med Chem; 2016; 16(2):81-97. PubMed ID: 26104056
[TBL] [Abstract][Full Text] [Related]
2. Herbal natural products as a source of monoamine oxidase inhibitors: a review.
Viña D; Serra S; Lamela M; Delogu G
Curr Top Med Chem; 2012; 12(20):2131-44. PubMed ID: 23231392
[TBL] [Abstract][Full Text] [Related]
3. [Monoamine oxidase as a target for drug action].
Drozak J; Kozłowski M
Postepy Hig Med Dosw (Online); 2006; 60():498-515. PubMed ID: 17060892
[TBL] [Abstract][Full Text] [Related]
4. A comprehensive review on synthesis and designing aspects of coumarin derivatives as monoamine oxidase inhibitors for depression and Alzheimer's disease.
Patil PO; Bari SB; Firke SD; Deshmukh PK; Donda ST; Patil DA
Bioorg Med Chem; 2013 May; 21(9):2434-50. PubMed ID: 23517722
[TBL] [Abstract][Full Text] [Related]
5. Clinical pharmacology of MAO inhibitors: safety and future.
Yamada M; Yasuhara H
Neurotoxicology; 2004 Jan; 25(1-2):215-21. PubMed ID: 14697896
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic applications of selective and non-selective inhibitors of monoamine oxidase A and B that do not cause significant tyramine potentiation.
Youdim MB; Weinstock M
Neurotoxicology; 2004 Jan; 25(1-2):243-50. PubMed ID: 14697899
[TBL] [Abstract][Full Text] [Related]
7. Rasagiline (TVP-1012): a new selective monoamine oxidase inhibitor for Parkinson's disease.
Guay DR
Am J Geriatr Pharmacother; 2006 Dec; 4(4):330-46. PubMed ID: 17296539
[TBL] [Abstract][Full Text] [Related]
8. Insights into the Mechanism of the Therapeutic Potential of Herbal Monoamine Oxidase Inhibitors in Neurological Diseases.
Mannan A; Singh TG; Singh V; Garg N; Kaur A; Singh M
Curr Drug Targets; 2022; 23(3):286-310. PubMed ID: 34238153
[TBL] [Abstract][Full Text] [Related]
9. Banisteriopsis caapi, a unique combination of MAO inhibitory and antioxidative constituents for the activities relevant to neurodegenerative disorders and Parkinson's disease.
Samoylenko V; Rahman MM; Tekwani BL; Tripathi LM; Wang YH; Khan SI; Khan IA; Miller LS; Joshi VC; Muhammad I
J Ethnopharmacol; 2010 Feb; 127(2):357-67. PubMed ID: 19879939
[TBL] [Abstract][Full Text] [Related]
10. Potential of Natural Products of Herbal Origin as Monoamine Oxidase Inhibitors.
Orhan IE
Curr Pharm Des; 2016; 22(3):268-76. PubMed ID: 26561069
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic, Molecular and Computational Aspects of Novel Monoamine Oxidase (MAO) Inhibitors.
Ramesh M; Dokurugu YM; Thompson MD; Soliman ME
Comb Chem High Throughput Screen; 2017; 20(6):492-509. PubMed ID: 28294055
[TBL] [Abstract][Full Text] [Related]
12. Monoamine Oxidase-B (MAO-B) Inhibitors in the Treatment of Alzheimer's and Parkinson's Disease.
Özdemir Z; Alagöz MA; Bahçecioğlu ÖF; Gök S
Curr Med Chem; 2021; 28(29):6045-6065. PubMed ID: 33538661
[TBL] [Abstract][Full Text] [Related]
13. [Inhibitory monoamine oxidases of the new generation].
Nowakowska E; Chodera A
Pol Merkur Lekarski; 1997 Jul; 3(13):1-4. PubMed ID: 9432289
[TBL] [Abstract][Full Text] [Related]
14. Monoamine Oxidase Inhibitors: From Classic to New Clinical Approaches.
Duarte P; Cuadrado A; León R
Handb Exp Pharmacol; 2021; 264():229-259. PubMed ID: 32852645
[TBL] [Abstract][Full Text] [Related]
15. Lights and shadows on monoamine oxidase inhibition in neuroprotective pharmacological therapies.
Binda C; Milczek EM; Bonivento D; Wang J; Mattevi A; Edmondson DE
Curr Top Med Chem; 2011 Nov; 11(22):2788-96. PubMed ID: 22039878
[TBL] [Abstract][Full Text] [Related]
16. The adenosine receptor affinities and monoamine oxidase B inhibitory properties of sulfanylphthalimide analogues.
Van der Walt MM; Terre'Blanche G; Petzer A; Petzer JP
Bioorg Chem; 2015 Apr; 59():117-23. PubMed ID: 25746740
[TBL] [Abstract][Full Text] [Related]
17. A comprehensive review of monoamine oxidase inhibitors as Anti-Alzheimer's disease agents: A review.
Manzoor S; Hoda N
Eur J Med Chem; 2020 Nov; 206():112787. PubMed ID: 32942081
[TBL] [Abstract][Full Text] [Related]
18. Potent Inhibition of Monoamine Oxidase B by a Piloquinone from Marine-Derived
Lee HW; Choi H; Nam SJ; Fenical W; Kim H
J Microbiol Biotechnol; 2017 Apr; 27(4):785-790. PubMed ID: 28068665
[TBL] [Abstract][Full Text] [Related]
19. Monoamine Oxidase Inhibitors Extracted from Tobacco Smoke as Neuroprotective Factors for Potential Treatment of Parkinson's Disease.
Sari Y; Khalil A
CNS Neurol Disord Drug Targets; 2015; 14(6):777-85. PubMed ID: 25808895
[TBL] [Abstract][Full Text] [Related]
20. Novel bifunctional drugs targeting monoamine oxidase inhibition and iron chelation as an approach to neuroprotection in Parkinson's disease and other neurodegenerative diseases.
Youdim MB; Fridkin M; Zheng H
J Neural Transm (Vienna); 2004 Oct; 111(10-11):1455-71. PubMed ID: 15480846
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
